Latest & greatest articles for simvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on simvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on simvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for simvastatin

21. Simvastatin: updated advice on drug interactions

Simvastatin: updated advice on drug interactions Simvastatin: updated advice on drug interactions Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Simvastatin: updated advice on drug interactions From: Published: 20 August 2012 Therapeutic area: and Updated contraindications and maximum dose recommendations when taken with a number of other medicines. Article date: August 2012 We have previously communicated on the increased risk of myopathy associated with use (...) of high-dose simvastatin (80 mg daily) – see . Considering the risk of myopathy associated with simvastatin, recent analysis of clinical trial data, spontaneously reported cases and drug- drug interaction studies has resulted in further changes to the simvastatin prescribing information. The changes include contraindications to concomitant use with certain medicines and maximum dose recommendations when simvastatin is taken with a number of other medicines, as these interactions may increase plasma

MHRA Drug Safety Update2012

22. Simvastatin: dose limitations with concomitant amlodipine or diltiazem

Simvastatin: dose limitations with concomitant amlodipine or diltiazem Simvastatin: dose limitations with concomitant amlodipine or diltiazem Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Simvastatin: dose limitations with concomitant amlodipine or diltiazem From: Published: 30 October 2012 Therapeutic area: and The maximum recommended dose for simvastatin in conjunction with amlodipine and diltiazem is now 20 mg/day. Article date: October 2012 Pharmacokinetic (...) data Simvastatin is metabolised through the CYP3A4 pathway. Concomitant use of CYP3A4 inhibitors has the potential to increase exposure to simvastatin . Both amlodipine and diltiazem are substrates and inhibitors of CYP3A4 and therefore increase the plasma concentration (AUC0-24h) and maximum plasma concentration (Cmax) of simvastatin when they are co-administered. Studies have found that after 10 days of amlodipine (10 mg), the AUC0-24h of simvastatin and simvastatic acid following a single dose

MHRA Drug Safety Update2012

23. The use of Simvastatin Plus Metformin Therapy in Patients With Polycystic Ovarian Syndrome

The use of Simvastatin Plus Metformin Therapy in Patients With Polycystic Ovarian Syndrome "The use of Simvastatin Plus Metformin Therapy in Patients With Polycys" by Erin Carrick < > > > > > Title Author Date of Award Summer 8-11-2012 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Robert P. Rosenow, Pharm.D., O.D. Second Advisor Annjanette Sommers PA-C, MS Rights . Abstract Background: Polycystic ovarian syndrome (PCOS) is a common (...) endocrine disorder that affects the fertility of reproductive-aged women due to high levels of testosterone. Metformin is currently used to treat patients with PCOS in order to improve the biochemical markers of the disease. New studies show that statin medications like simvastatin may prove efficacious with reduction of testosterone levels, and therefore, possibly increase fertility. Methods: An extensive search of MEDLINE, CINAHL, Web of Science, and EBM Multifiles was conducted. Articles that were

Pacific University EBM Capstone Project2012

24. Weighing the Benefits of High-Dose Simvastatin against the Risk of Myopathy.

Weighing the Benefits of High-Dose Simvastatin against the Risk of Myopathy. Weighing the benefits of high-dose simvastatin against the risk of myopathy. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 21675881 (...) Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 Jul 28;365(4):285-7. doi: 10.1056/NEJMp1106689. Epub 2011 Jun 15. Weighing the benefits of high-dose simvastatin against the risk of myopathy. 1 , . 1 Division of Metabolism and Endocrinology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food

NEJM2011

25. FDA issues new dosing limitations for Simvastatin

FDA issues new dosing limitations for Simvastatin Breaking News: FDA issues new dosing limitations for Simvastatin | Clinical Correlations Breaking News: FDA issues new dosing limitations for Simvastatin June 10, 2011 By Saleem Ali, MD The FDA has issued new warnings regarding the use of high dose Simvastatin. The FDA is now recommending that the 80mg dose only be used in patients who have been taking that dosage for at least 12 months with no signs of toxicity. Patients who are currently (...) on simvastatin and require more than 40 mg. should be considered for alternative lipid lowering therapy. The FDA is issuing this warning because recent data has shown that the 80 mg. dose has a significantly higher risk of rhabdomyolsysis and muscle injury than lower doses. Leading to this alert was a preliminary analysis of the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) trial. The purpose of this randomized controlled trial was to determine if more intensive

Clinical Correlations2011

26. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. 22115874 2011 12 14 2011 12 29 2016 12 03 1474-547X 378 9808 2011 Dec 10 Lancet (London, England) Lancet Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. 2013-20 10.1016/S0140-6736(11)61125-2 Findings (...) of vascular and non-vascular outcomes were allocated either 40 mg simvastatin daily or placebo, using minimised randomisation. Mean in-trial follow-up was 5·3 years (SD 1·2), and post-trial follow-up of surviving patients yielded a mean total duration of 11·0 years (SD 0·6). The primary outcome of the long-term follow-up of HPS was first post-randomisation major vascular event, and analysis was by intention to treat. This trial is registered with ISRCTN, number 48489393. During the in-trial period

Lancet2011 Full Text: Link to full Text with Trip Pro

27. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. 21663949 2011 06 27 2011 07 18 2016 12 28 1474-547X 377 9784 2011 Jun 25 Lancet (London, England) Lancet The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. 2181-92 (...) 10.1016/S0140-6736(11)60739-3 Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients. This randomised double-blind trial included 9270 patients with chronic kidney disease

Lancet2011 Full Text: Link to full Text with Trip Pro

28. SHARP: Study of Heart & Renal Protection - The Effects of Lowering LDL Cholesterol with Simvastatin plus Ezetimibe in Patients with Chronic Kidney Disease

SHARP: Study of Heart & Renal Protection - The Effects of Lowering LDL Cholesterol with Simvastatin plus Ezetimibe in Patients with Chronic Kidney Disease

RxFiles2011

29. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults >/=65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study)

Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults >/=65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study) 21029821 2010 10 29 2010 12 02 2015 11 19 1879-1913 106 9 2010 Nov 01 The American journal of cardiology Am. J. Cardiol. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with (...) and safety of the usual starting dose of ezetimibe/simvastatin (10/20 mg) versus atorvastatin 10 or 20 mg and the next higher dose of ezetimibe/simvastatin (10/40 mg) versus atorvastatin 40 mg in 1,289 hypercholesterolemic patients ≥65 years of age with or without cardiovascular disease. Patients randomized to ezetimibe/simvastatin had greater percent decreases in LDL cholesterol (-54.2% for 10/20 mg vs -39.5% and -46.6% for atorvastatin 10 and 20 mg, respectively; -59.1% for 10/40 mg vs -50.8

EvidenceUpdates2010

30. Simvastatin in the treatment of asthma: lack of steroid-sparing effect

Simvastatin in the treatment of asthma: lack of steroid-sparing effect 20861293 2010 09 23 2010 10 29 2015 11 19 1468-3296 65 10 2010 Oct Thorax Thorax Simvastatin in the treatment of asthma: lack of steroid-sparing effect. 891-6 10.1136/thx.2010.138990 Statins have anti-inflammatory actions which in theory are potentially beneficial in asthma. Small trials have failed to show a significant benefit, but a systematic study to evaluate the steroid-sparing effect of statin treatment has not been (...) carried out. A randomised, placebo-controlled, crossover trial was conducted of simvastatin 40 mg at night with simultaneous stepwise reduction of fluticasone propionate dose until loss of control occurred, followed by an increase until regain of control ('minimum' dose required) in 51 patients with asthma and sputum eosinophils (steroid-free) ≥ 2%. 43 patients completed the study. There was no significant difference in 'minimum' inhaled corticosteroid (ICS) dose requirement between simvastatin

EvidenceUpdates2010

31. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets

Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets 20487050 2010 07 20 2011 11 10 2015 11 19 1742-1241 64 8 2010 Jul International journal of clinical practice Int. J. Clin. Pract. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised (...) controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. 1052-61 10.1111/j.1742-1241.2010.02429.x The aim of this study was to compare ezetimibe/simvastatin combination therapy with intensified statin monotherapy as alternative treatment strategies to achieve the Joint British Societies (JBS)-2 and National Institute for Health and Clinical Excellence low-density-lipoprotein cholesterol (LDL-C) target of < 2 mmol/l for secondary prevention or JBS-2 LDL-C target of < 2 mmol

EvidenceUpdates2010

32. Simvastatin as a treatment for pulmonary hypertension trial

Simvastatin as a treatment for pulmonary hypertension trial 20460548 2010 05 12 2010 06 09 2016 12 15 1535-4970 181 10 2010 May 15 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Simvastatin as a treatment for pulmonary hypertension trial. 1106-13 10.1164/rccm.2009111-699OC In animal models of pulmonary hypertension, simvastatin has been shown to reduce pulmonary artery pressure and induce regression of associated right ventricular (RV) hypertrophy (...) . To assess the therapeutic value of simvastatin in patients with pulmonary arterial hypertension (PAH). Forty-two patients with PAH were randomized to receive either simvastatin (80 mg/d) or placebo in addition to current care for 6 months, and thereafter offered open-label simvastatin. The primary outcome was change in RV mass, assessed by cardiac magnetic resonance (CMR). At 6 months, RV mass decreased by 5.2 +/- 11 g in the statin group (P = 0.045) and increased 3.9 +/- 14 g in the placebo group

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

33. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER)

Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER) 20102893 2010 01 27 2010 03 04 2015 11 19 1879-1913 105 1 2010 Jan 01 The American journal of cardiology Am. J. Cardiol. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). 69-76 10.1016/j.amjcard.2009.08.651 (...) Statins are the most commonly prescribed agents for lowering levels of low-density lipoprotein (LDL) cholesterol. Although dose-dependent reductions in levels of atherogenic lipids are observed with all statins, the impact of increasing dose has not been fully elucidated. An individual patient data pooled analysis was performed of 32,258 patients in studies comparing the efficacy of rosuvastatin with that of atorvastatin or simvastatin. The impact of increasing dose on lowering LDL cholesterol

EvidenceUpdates2010

34. Simvastatin: increased risk of myopathy at high dose (80 mg)

Simvastatin: increased risk of myopathy at high dose (80 mg) Simvastatin: increased risk of myopathy at high dose (80 mg) Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Simvastatin: increased risk of myopathy at high dose (80 mg) From: Published: 1 May 2010 Therapeutic area: There is an increased risk of myopathy associated with high-dose (80 mg) simvastatin. The 80-mg dose should be considered only in patients with severe hypercholesterolaemia and high risk (...) of cardiovascular complications who have not achieved their treatment goals on lower doses, when the benefits are expected to outweigh the potential risks Article date: May 2010 The simvastatin (Zocor) product information (Summary of Product Characteristics and Patient Information Leaflet) has been updated to include warnings about increased risk of myopathy in patients receiving the highest licensed dose (80 mg). Similar changes are being implemented to the product information for combination products

MHRA Drug Safety Update2010

35. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study

Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study Reckless J, Davies G, Tunceli K, Hu XH, Brudi P Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of switching to a combination of ezetimibe and simvastatin, compared with doubling the statin dose, for patients with acute coronary syndrome, who had

NHS Economic Evaluation Database.2010

36. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. 21067805 2010 11 15 2010 12 16 2016 12 03 1474-547X 376 9753 2010 Nov 13 Lancet (London, England) Lancet Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. 1658-69 10.1016/S0140-6736(10)60310-8 Lowering of LDL cholesterol reduces (...) if already on a statin or 4·5 mmol/L if not. Randomisation to either 80 mg or 20 mg simvastatin daily was done centrally using a minimisation algorithm. Participants were assessed at 2, 4, 8, and 12 months after randomisation and then every 6 months until final follow-up. The primary endpoint was major vascular events, defined as coronary death, myocardial infarction, stroke, or arterial revascularisation. Analysis was by intention to treat. This study is registered, number ISRCTN74348595. 6031

Lancet2010 Full Text: Link to full Text with Trip Pro

37. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)

Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study) 19539078 2009 06 22 2009 07 14 2015 11 19 1879-1913 103 12 2009 Jun 15 The American journal of cardiology Am. J. Cardiol. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). 1694-702 10.1016/j.amjcard.2009.05.003 (...) Patients with the metabolic syndrome are at an increased risk of cardiovascular disease and might require intensive lipid therapy. Many patients remain at the starting dose of lipid therapy and might not be titrated up to a higher dose. The present double-blind, randomized, 6-week study assessed the lipid-lowering efficacy of ezetimibe/simvastatin 10/20 mg versus atorvastatin 10 or 20 mg, and ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in 1,128 patients with hypercholesterolemia and the

EvidenceUpdates2009

38. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction

Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction 19427432 2009 05 11 2009 06 05 2015 11 19 1879-1913 103 10 2009 May 15 The American journal of cardiology Am. J. Cardiol. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction. 1381-5 10.1016/j.amjcard (...) .2009.01.377 We investigated whether intensive cholesterol lowering could more effectively prevent heart failure (HF) in secondary prevention. The IDEAL study was a 4.8-year prospective, randomized trial comparing "usual" simvastatin treatment (20 to 40 mg/day, n = 4,449) with high-dose atorvastatin (80 mg/day, n = 4,439) in patients with a history of myocardial infarction (MI). At baseline, 94% of patients (n = 8,351) had no history of HF. During the course of the trial, there were 222 new or recurrent

EvidenceUpdates2009

39. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease

Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease 19231315 2009 02 23 2009 03 27 2015 11 19 1879-1913 103 5 2009 Mar 01 The American journal of cardiology Am. J. Cardiol. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering (...) [IDEAL] study). 577-82 10.1016/j.amjcard.2008.10.029 The efficacy and safety of atorvastatin (80 mg/day) versus simvastatin (20 to 40 mg/day) in older (age >or=65 years) versus younger (<65 years) patients were assessed in a prespecified secondary analysis of the 8,888 patients with myocardial infarction in the IDEAL trial, a randomized open-label study. Several cardiovascular end points were evaluated, including the occurrence of a first major coronary event (MCE; nonfatal myocardial infarction

EvidenceUpdates2009

40. Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial

Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial (...) Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial Wagner M, Lindgren P, Merikle E, Goetghebeur M, Jonsson B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions

NHS Economic Evaluation Database.2009